NASDAQ:DSGN

Design Therapeutics News Headlines

$26.38
-1.93 (-6.82 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.04
$28.06
50-Day Range
$19.02
$41.49
52-Week Range
$18.81
$50.50
Volume33,499 shs
Average Volume180,235 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Design Therapeutics (NASDAQ DSGN) News Headlines Today

SourceHeadline
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial ResultsDesign Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
markets.businessinsider.com - May 10 at 9:12 PM
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial ResultsDesign Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 9:12 PM
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up to $26.58Design Therapeutics (NASDAQ:DSGN) Shares Gap Up to $26.58
americanbankingnews.com - May 10 at 2:43 PM
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeDesign Therapeutics (NASDAQ:DSGN) Sees Strong Trading Volume
americanbankingnews.com - May 7 at 11:54 AM
Design Therapeutics (NASDAQ:DSGN) Trading Up 5.8%Design Therapeutics (NASDAQ:DSGN) Trading Up 5.8%
americanbankingnews.com - May 3 at 12:46 PM
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up to $22.69Design Therapeutics (NASDAQ:DSGN) Shares Gap Up to $22.69
americanbankingnews.com - April 30 at 11:02 AM
Zacks: Analysts Anticipate Design Therapeutics, Inc. (NASDAQ:DSGN) to Post -$0.06 Earnings Per ShareZacks: Analysts Anticipate Design Therapeutics, Inc. (NASDAQ:DSGN) to Post -$0.06 Earnings Per Share
americanbankingnews.com - April 30 at 6:20 AM
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous PemphigoidAkari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
benzinga.com - April 28 at 9:42 AM
Design Therapeutics, Inc.s (NASDAQ:DSGN) Quiet Period Will Expire  on May 5thDesign Therapeutics, Inc.'s (NASDAQ:DSGN) Quiet Period Will Expire on May 5th
americanbankingnews.com - April 28 at 1:24 AM
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsCRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
markets.businessinsider.com - April 27 at 6:57 PM
Design Therapeutics (NASDAQ:DSGN) Trading 5.8% Higher Design Therapeutics (NASDAQ:DSGN) Trading 5.8% Higher
americanbankingnews.com - April 27 at 11:38 AM
Dyno Therapeutics Names Dr. Debora Marks and Dr. Nicole Paulk to Scientific Advisory BoardDyno Therapeutics Names Dr. Debora Marks and Dr. Nicole Paulk to Scientific Advisory Board
businesswire.com - April 26 at 2:44 PM
The Goldman Sachs Group Initiates Coverage on Design Therapeutics (NASDAQ:DSGN)The Goldman Sachs Group Initiates Coverage on Design Therapeutics (NASDAQ:DSGN)
americanbankingnews.com - April 26 at 11:00 AM
Design Therapeutics (NASDAQ:DSGN) Now Covered by Piper SandlerDesign Therapeutics (NASDAQ:DSGN) Now Covered by Piper Sandler
americanbankingnews.com - April 26 at 11:00 AM
Design Therapeutics (NASDAQ:DSGN) Now Covered by Analysts at SVB LeerinkDesign Therapeutics (NASDAQ:DSGN) Now Covered by Analysts at SVB Leerink
americanbankingnews.com - April 26 at 11:00 AM
Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United StatesNeoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States
markets.businessinsider.com - April 26 at 8:29 AM
THC Therapeutics, Inc: THC Therapeutics Has Completed the dHydronator Consumer Model DesignTHC Therapeutics, Inc: THC Therapeutics Has Completed the dHydronator Consumer Model Design
finanznachrichten.de - April 23 at 1:34 PM
Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase ModulatorsAnavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators
benzinga.com - April 22 at 9:50 AM
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein TherapeuticsVyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
markets.businessinsider.com - April 22 at 9:50 AM
Design Therapeutics, Inc. to Post Q1 2021 Earnings of ($0.05) Per Share, Piper Sandler Forecasts (NASDAQ:DSGN)Design Therapeutics, Inc. to Post Q1 2021 Earnings of ($0.05) Per Share, Piper Sandler Forecasts (NASDAQ:DSGN)
americanbankingnews.com - April 22 at 8:18 AM
Analysts Offer Predictions for Design Therapeutics, Inc.s Q1 2021 Earnings (NASDAQ:DSGN)Analysts Offer Predictions for Design Therapeutics, Inc.'s Q1 2021 Earnings (NASDAQ:DSGN)
americanbankingnews.com - April 22 at 8:18 AM
PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeuticsPRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics
ca.finance.yahoo.com - April 21 at 6:52 PM
Design Therapeutics (NASDAQ:DSGN) Trading Down 7.2%Design Therapeutics (NASDAQ:DSGN) Trading Down 7.2%
americanbankingnews.com - April 21 at 11:43 AM
Nimbus Therapeutics Expands Development Team to Advance Multiple Portfolio Programs Through Clinical TestingNimbus Therapeutics Expands Development Team to Advance Multiple Portfolio Programs Through Clinical Testing
ca.finance.yahoo.com - April 21 at 8:52 AM
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year Low at $21.06Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year Low at $21.06
americanbankingnews.com - April 20 at 3:32 PM
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.
ca.finance.yahoo.com - April 20 at 2:20 PM
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated at SVB LeerinkDesign Therapeutics (NASDAQ:DSGN) Coverage Initiated at SVB Leerink
americanbankingnews.com - April 20 at 10:52 AM
THC Therapeutics Has Completed the dHydronator® Consumer Model Design with photosTHC Therapeutics Has Completed the dHydronator® Consumer Model Design with photos
markets.businessinsider.com - April 20 at 9:19 AM
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated at The Goldman Sachs GroupDesign Therapeutics (NASDAQ:DSGN) Coverage Initiated at The Goldman Sachs Group
americanbankingnews.com - April 20 at 8:02 AM
Piper Sandler Initiates Coverage on Design Therapeutics (NASDAQ:DSGN)Piper Sandler Initiates Coverage on Design Therapeutics (NASDAQ:DSGN)
americanbankingnews.com - April 20 at 8:02 AM
ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021
au.finance.yahoo.com - April 19 at 1:03 PM
Global Stroke Diagnostics and Therapeutics Market 2020 Industrial Trends, Consumption Volume, Key Tactics and Competitive Strategies by 2026Global Stroke Diagnostics and Therapeutics Market 2020 Industrial Trends, Consumption Volume, Key Tactics and Competitive Strategies by 2026
marketwatch.com - April 19 at 12:45 AM
Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical TrialStuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical Trial
markets.businessinsider.com - April 16 at 5:02 PM
PTSD Therapeutics Market Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2021-2025PTSD Therapeutics Market Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2021-2025
marketwatch.com - April 16 at 7:00 AM
Peptide Therapeutics Market 2015-2025 Global Analysis, Size, Share, Incredible Growth, Detailed Industry Analysis and Business Prospects | FMIPeptide Therapeutics Market 2015-2025 Global Analysis, Size, Share, Incredible Growth, Detailed Industry Analysis and Business Prospects | FMI
marketwatch.com - April 15 at 3:25 PM
Zelira Therapeutics well-placed to capitalise on expanding global medicinal cannabis sectorZelira Therapeutics well-placed to capitalise on expanding global medicinal cannabis sector
proactiveinvestors.com - April 8 at 9:38 AM
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare ConferenceCRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 9:39 AM
Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of FinanceCedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance
businesswire.com - April 5 at 1:11 PM
Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology EcosystemAlloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem
businesswire.com - April 2 at 12:58 PM
Design Therapeutics Inc (DSGN) COO Sean Jeffries Bought $61,000 of SharesDesign Therapeutics Inc (DSGN) COO Sean Jeffries Bought $61,000 of Shares
finance.yahoo.com - April 2 at 12:52 AM
BRIEF-Scribe Therapeutics Raises $100 Mln Series B FinancingBRIEF-Scribe Therapeutics Raises $100 Mln Series B Financing
msn.com - March 31 at 1:48 PM
A New Approach To CRISPR - Scribe Therapeutics Designs Novel CRISPR MoleculesA New Approach To CRISPR - Scribe Therapeutics Designs Novel CRISPR Molecules
forbes.com - March 31 at 1:48 PM
Mirati Therapeutics Board Elects Shalini Sharp as New Independent DirectorMirati Therapeutics Board Elects Shalini Sharp as New Independent Director
markets.businessinsider.com - March 31 at 8:47 AM
Design Therapeutics IncDesign Therapeutics Inc
reuters.com - March 31 at 8:47 AM
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesDesign Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - March 31 at 8:47 AM
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.